Library References
|
|
|
|
|
|
|
|
You need to upgrade your Flash Player This is replaced by the Flash content.
Place your alternate content here and users without the Flash plugin or with
Javascript turned off will see this. Content here allows you to leave out
noscript tags. Include a link to bypass the detection if you wish. You need to upgrade your Flash Player This is replaced by the Flash content.
Place your alternate content here and users without the Flash plugin or with
Javascript turned off will see this. Content here allows you to leave out
noscript tags. Include a link to bypass the detection if you wish. You need to upgrade your Flash Player This is replaced by the Flash content.
Place your alternate content here and users without the Flash plugin or with
Javascript turned off will see this. Content here allows you to leave out
noscript tags. Include a link to bypass the detection if you wish. You need to upgrade your Flash Player This is replaced by the Flash content.
Place your alternate content here and users without the Flash plugin or with
Javascript turned off will see this. Content here allows you to leave out
noscript tags. Include a link to bypass the detection if you wish. Library References
| Author(s) | Kaufman, K.D. |
| Title | Long-term (5-year) multinational experience with finasteride 1mg in the treatment of men with androgenetic alopecia / The finasteride male pattern hair loss study group |
| Journal Name | European Journal of Dermatology |
| Journal Citation | Eur J Dermatol 2002; 12: 38-49 |
| Date Published | January-February 2002 |
| Author(s) | Kaufman |
| Title | Finasteride in the Treatment of Men with Androgenetic Alopecia |
| Journal Name | Finasteride Male Pattern Hair Loss Study Group |
| Journal Citation | Journal of the American Academy of Dermatology |
| Date Published | 1998 Oct.; 39(4 Pt 1): 578-89 October 1998 |
| Author(s) | Leyden |
| Title | Finasteride in the Treatment of Men with Frontal Male Pattern Hair Loss |
| Journal Name | Journal of the American Academy of Dermatology |
| Journal Citation | Vol. 40, No. 6 Part 1, June 1999; Page(s) 930-7 |
| Date Published | June 1999 |
| Summary | The "Frontal" data demonstrate the efficacy
of PROPECIA in the treatment of men with frontal male pattern hair loss (MPHL). This is a key differentiating
advantage over minoxidil, which has not been shown to
affect frontal hair growth. After two years of treatment
with PROPECIA:
|
| Author(s) | Kaufman |
| Title | Androgen Metabolism As It Affects Hair Growth in Androgenetic Alopecia |
| Journal Name | Dermatologic Clinics |
| Journal Citation | Vol. 14, No. 4, Oct. 1996, 697-711 |
| Date Published | 1996 |
| Author(s) | Sawaya |
| Title | Different Levels of 5A-Reductase Type I and II Aromatase, And Androgen |
| Journal Name | Receptor In Hair Follicles of Women And Men With Androgenetic Alopecia |
| Journal Citation | Journal of Investigative Dermatology |
| Date Published | Vol. 109, No. 3, Sept. 1997, 296-300 1997 |
| Author(s) | Passchier |
| Title | Quality of Life Issues in Male Pattern Hair Loss |
| Journal Name | Dermatology |
| Journal Citation | Vol. 197, 1998, Page(s) 217-218 |
| Date Published | 1998 |
| Summary | Although not a serious disease, male pattern hair loss (MPHL) is quite common and can have a significant negative imapct on the quality of life (QOL) of those men who experience it. Hair growth and hair style are important elements of an individual's identity as perceived by themselves as well as by others. Considering the fact that through history, hair has been associated with social importance, it is not surprising that hair loss may have a potentially adverse impact on a person's QOL. Unfortunately, sometimes the impact on QOL is trivialised or even ignored by those affected by it. Studies have shown that men with visible hair loss are generally seen by others as being significantly older, less physically or socially attractive, weaker, and less potent than their peers. this article discusses the importance and impact of hair loss on the QOL of individuals that experience MPHL, as well as some misconceptions shared by the general public. |
| View Paper (PDF) |  Click
to view Paper (Right-Click to Download) |
| Author(s) | Whiting |
| Title | Male Pattern Hair Loss; Current Understanding |
| Journal Name | International Journal of Dermatology |
| Journal Citation | Vol. 37: 8, 1998, Pages(s) 561-566 |
| Date Published | 1998 |
| Summary | Androgenetic alopecia is the most common form of human hair loss. It affects at least 50 percent of men by the age of 50 years and close to 50 percent of women by the age of 60 years. This article reviews the history and current understanding of male pattern hair loss (MPHL). Historically, observations have suggested that androgenetic alopecia/MPHL results from a combination of heredity and hormones. Scientific observations have been obscured by anecdote and speculation, and not all medical and dermatologic textbooks have given hair loss serious consideration. Now, however, a better understanding of the molecular biology of hair growth in MPHL has indicated a new approach to treatment. This new approach involves the inhibition of 5 alpha-reductase, the enzyme that reduces testosterone to its more active form, dihydrotestosterone (DHT). DHT is currently thought to be the most potent androgen affecting the human hair growth cycle, with adverse effects in MPHL. This article summarizes the current knowledge of normal scalp hair growth, hormonal and enzyme mediators, and the changes that occur in androgenetic alopecia, which may be modulated by 5 alpha-reductase inhibition. |
| Author(s) | Girman |
| Title | Effects of Self-Perceived Hair Loss in a Community Sample of Men |
| Journal Name | Dermatology |
| Journal Citation | 1998: 197(3): 223-9 |
| Date Published | 1998 |
| Summary | Men with male pattern hair loss (MPHL) are more dissatisfied
with the appearance of their hair and are more self-conscious
about their hair than men with little or no hair loss.
This is the finding of Girman et al in a cross-sectional
survey of a community sample of men not seeking medical
treatment for hair loss. The objective of this study was to characterize the relationship of self-perception to hair loss with the degree of bother, concern about getting older, perceived noticeability to others , and dissatisfaction with hair appearance to hair loss, using a standardized instrument addressing these specific concerns. The study used community sampling to reduce the potential bias associated with studying the effects of hair loss in men seeking medical treatment. Key Findings:
|
| View Paper (PDF) | Click
to view Paper (Right-Click to Download) |
| Author(s) | Cash |
| Title | The Psychological Effects of Androgenetic Alopecia in Men |
| Journal Name | Journal of the American Academy of Dermatology |
| Journal Citation | Vol. 26, No. 6, June 1992, Page(s): 926-931 |
| Date Published | 1992 |
| Author(s) | Sasmaz S. |
| Title | The Risk of Coronary Heart Disease in Men with Androgenetic Alopecia |
| Journal Name | Journal of the European Academy of Dermatology and Venereology |
| Journal Citation | 1999 Mar.; 12(2): 123-5 |
| Date Published | March 1999 |
| Summary | This study determines the significance of certain lipid parameters on this relationship between AGA and coronary heart disease. It focuses on the importance of lipid parameters like total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, lipoprotein (a), apolipoprotein A1, and apolipoprotein B in patients with androgenetic alopecia. The study consisted of 41 men with vertex-type androgenetic alopecia and 36 men (same ages) with normal hair status. The most remarkable result of this study is the significantly higher levels of lipoprotein (a) in patients with androgenetic alopecia, because lipoprotein (a) is an important independent and genetically determined risk factor for coronary heart disease. The results of the study indicate that men with androgenetic alopecia present a higher risk for coronary heart disease than men with normal hair status. In conclusion, the study suggests that dermatologists investigate lipid profiles of patients with androgenetic alopecia and consider advising them to consult a cardiologist if necessary. |
| Author(s) | Paus R. |
| Title | The Biology of Hair Follicles |
| Journal Name | New England Journal of Medicine |
| Journal Citation | 1999 Aug.; 12:34(7): 491-7 |
| Date Published | August 1999 |
| Summary | In this discussion of the biology of hair, the pathobiology of androgenetic alopecia is discussed, along with the two currently available treatments: PROPECIA and topical minoxidil. PROPECIA is described as an effective means of slowing or reversing the progression of androgenetic alopecia due to inhibition of 5-alpha reductase, resulting in the inhibition of androgen-dependent miniaturization of hair follicles. The 24-month data are cited as supporting evidence of the efficacy of PROPECIA in men with male pattern hair loss (MPHL). In contrast, the effects of minoxidil are described as variable and occurring in only a minority of patients. |
| Author(s) | Overstreet |
| Title | Chronic Treatment with Finasteride Daily Does Not Affect |
| Journal Name | Spermatogenesis of Semen Production in Young Men |
| Journal Citation | Journal of Urology |
| Date Published | 1999 Oct.; 162(4): 1295-300 October 1999 |
| Summary | Key findings in the study show that finasteride 1 mg did not affect spermatogenesis or semen production in young men. Its effects on prostate volume and serum PSA in these men were small and reversible on discontinuation of the drug. The study is the longest placebo-controlled trial evaluating semen parameters using strict quality-controlled methodology. 181 healthy men participated in a semen analysis subset. The protocol consisted of a single-blind, 2-week placebo run-in period followed by a randomized double-blind, placebo-controlled period of 48 weeks in which 91 men received finasteride 1 mg daily and 90 received placebo for 48 weeks, followed by a 60-week off-drug reversibility period. The absence of any clinically relevant effects of finasteride 1 mg on semen parameters, despite significant changes in serum DHT, indicates that testosterone, not dihydrotestosterone appears to be the primary androgen regulating spermatogenesis and sperm quality (sperm concentration, morphology, motility, and fertilizing capability). Sexual adverse experiences occurred in a small number of men, consistent with results observed in a similar population in larger clinical trials. |
| Author(s) | Lutufo P. |
| Title | Male pattern baldness and coronary heart disease: The Physician's Health Study. |
| Journal Name | Archives of internal Medicine |
| Journal Citation | 2000 Jan 24; 160(2): 165-71 |
| Date Published | 2000 |
| Summary | Vertex pattern baldness appears to be a marker for increased risk of coronary events, especially in men with hypertension or hypercholesterolemia. This finding is reported by investigators from the Physicians' Health Study, a retrospective cohort study among 22,071 US male physicians 40 to 84 years of age. Of these, 19,112 were free of coronary heart disease (CHD) (nonfatal myocardial infarction [MI], angina pectoris, and/or coronary revascularization) at baseline and completed a questionnaire at the 11-year follow-up concerning their pattern of hair loss at age 45. Response options included no hair loss, frontal baldness only, or frontal baldness with mild, moderate, or severe vertex baldness. Results: During 11 years of follow-up, 1446 CHD events were documented. Compared with men with no hair loss, those with frontal baldness had an age-adjusted relative risk of CHD of 1.09, while those with mild, moderate, or severe vertex baldness had a relative risk of 1.23, 1.32, and 1.36, respectively. Multivariate adjustment for age, parental history of MI, height, body mass index, smoking, history of hypertension, diabetes, high cholesterol level, physical activity, and alcohol intake did not materially alter these associations. Results were similar when nonfatal MI, angina, and coronary revascularization were examined separately, and when events were analyzed among men older and younger than 55 years at baseline. Vertex baldness was more strongly associated with CHD risk among men with hypertension or high cholesterol levels. |